Gorezis Spyridon, Asproudis Ioannis, Chalasios Nikolaos, Karali Aikaterini, Tsanou Elena, Peschos Dimitrios, Christodoulou Aikaterini, Aspiotis Miltiadis
Epirus Vision Center, Ioannina, Greece.
Open Ophthalmol J. 2010 Jul 29;4:39-41. doi: 10.2174/1874364101004010039.
Evaluation of contrast sensitivity in patients with beta-thalassemia major and sickle cell disease which undergo regular transfusions and chelation therapy with desferrioxamine (DFX).
We studied contrast sensitivity in 48 eyes (24 patients) with beta-thalassemia major (group A) and in 42 eyes (21 patients) with sickle cell disease (group B), compared to 60 eyes of 30 healthy individuals (control group). Contrast sensitivity was measured using B-VAT II-SG Mentor Video Aquity Tester.
We found no statistically significant difference between group A and group B in any spatial frequency, while we found statistically significant differences between group B and control group in all spatial frequencies studied. Between group A and control group we found statistically significant differences in spatial frequencies of 2.3, and 6 cyc/deg.
DFX causes retinal alterations that may explain reductions in contrast sensitivity function and justifies regular evaluations that may allow early detection of visual function deterioration.
评估重型β地中海贫血和镰状细胞病患者在接受定期输血和去铁胺（DFX）螯合治疗后的对比敏感度。
我们研究了48只眼（24例患者）的重型β地中海贫血（A组）和42只眼（21例患者）的镰状细胞病（B组）的对比敏感度，并与30名健康个体的60只眼（对照组）进行比较。使用B-VAT II-SG Mentor Video Aquity Tester测量对比敏感度。
我们发现A组和B组在任何空间频率上均无统计学显著差异，而在所有研究的空间频率上，我们发现B组与对照组之间存在统计学显著差异。在A组和对照组之间，我们发现在2.3和6周/度的空间频率上存在统计学显著差异。
DFX会引起视网膜改变，这可能解释了对比敏感度功能的降低，并证明定期评估是合理的，因为这可能有助于早期发现视觉功能恶化。
Zotero 插件